CL2020003319A1 - Receptores del factor de crecimiento quiméricos - Google Patents
Receptores del factor de crecimiento quiméricosInfo
- Publication number
- CL2020003319A1 CL2020003319A1 CL2020003319A CL2020003319A CL2020003319A1 CL 2020003319 A1 CL2020003319 A1 CL 2020003319A1 CL 2020003319 A CL2020003319 A CL 2020003319A CL 2020003319 A CL2020003319 A CL 2020003319A CL 2020003319 A1 CL2020003319 A1 CL 2020003319A1
- Authority
- CL
- Chile
- Prior art keywords
- cells
- growth factor
- effort
- chimeric growth
- factor receptors
- Prior art date
Links
- 102000009465 Growth Factor Receptors Human genes 0.000 title abstract 2
- 108010009202 Growth Factor Receptors Proteins 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 abstract 1
- 229960001069 eltrombopag Drugs 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810181.6A GB201810181D0 (en) | 2018-06-21 | 2018-06-21 | Cells expressing chimeric recominant growth factor receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003319A1 true CL2020003319A1 (es) | 2021-07-09 |
Family
ID=63042840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003319A CL2020003319A1 (es) | 2018-06-21 | 2020-12-21 | Receptores del factor de crecimiento quiméricos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210205365A1 (enExample) |
| EP (1) | EP3810646A1 (enExample) |
| JP (2) | JP2021527425A (enExample) |
| KR (1) | KR20210022690A (enExample) |
| CN (1) | CN112601759A (enExample) |
| AU (1) | AU2019289202B2 (enExample) |
| BR (1) | BR112020026233A2 (enExample) |
| CA (1) | CA3104079A1 (enExample) |
| CL (1) | CL2020003319A1 (enExample) |
| CO (1) | CO2020016052A2 (enExample) |
| CR (1) | CR20200624A (enExample) |
| EA (1) | EA202190100A1 (enExample) |
| EC (1) | ECSP20082338A (enExample) |
| GB (1) | GB201810181D0 (enExample) |
| IL (1) | IL279469A (enExample) |
| MX (1) | MX2020014257A (enExample) |
| PH (1) | PH12020500678A1 (enExample) |
| SG (1) | SG11202012726QA (enExample) |
| WO (1) | WO2019243835A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| WO2021173586A1 (en) * | 2020-02-24 | 2021-09-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| EP4263807A2 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| CA3205464A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| EP4370139A4 (en) | 2021-07-14 | 2025-10-15 | Synthekine Inc | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE |
| CN122094708A (zh) * | 2023-10-03 | 2026-05-26 | 美国政府(由卫生和人类服务部的部长所代表) | 表达嵌合造血生长因子受体的nk细胞或t细胞及使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20011026A3 (cs) * | 1998-09-23 | 2001-08-15 | Zymogenetics, Inc. | Izolovaný polynukleotid, expresní vektor, kultivovaná buňka, konstrukt DNA, způsob produkce proteinu, izolovaný polypeptid, způsob produkce protilátky, protilátka a způsob detekce |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| WO2015188141A2 (en) * | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| GB201522097D0 (en) * | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| WO2018175476A1 (en) * | 2017-03-20 | 2018-09-27 | Baylor College Of Medicine | Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells |
-
2018
- 2018-06-21 GB GBGB1810181.6A patent/GB201810181D0/en not_active Ceased
-
2019
- 2019-06-21 EP EP19739687.2A patent/EP3810646A1/en not_active Withdrawn
- 2019-06-21 CN CN201980055314.2A patent/CN112601759A/zh active Pending
- 2019-06-21 AU AU2019289202A patent/AU2019289202B2/en not_active Expired - Fee Related
- 2019-06-21 JP JP2020570748A patent/JP2021527425A/ja not_active Ceased
- 2019-06-21 WO PCT/GB2019/051745 patent/WO2019243835A1/en not_active Ceased
- 2019-06-21 BR BR112020026233-1A patent/BR112020026233A2/pt not_active IP Right Cessation
- 2019-06-21 SG SG11202012726QA patent/SG11202012726QA/en unknown
- 2019-06-21 MX MX2020014257A patent/MX2020014257A/es unknown
- 2019-06-21 KR KR1020217001790A patent/KR20210022690A/ko not_active Withdrawn
- 2019-06-21 CR CR20200624A patent/CR20200624A/es unknown
- 2019-06-21 EA EA202190100A patent/EA202190100A1/ru unknown
- 2019-06-21 CA CA3104079A patent/CA3104079A1/en active Pending
-
2020
- 2020-12-15 IL IL279469A patent/IL279469A/en unknown
- 2020-12-17 US US17/124,922 patent/US20210205365A1/en not_active Abandoned
- 2020-12-18 EC ECSENADI202082338A patent/ECSP20082338A/es unknown
- 2020-12-18 PH PH12020500678A patent/PH12020500678A1/en unknown
- 2020-12-21 CO CONC2020/0016052A patent/CO2020016052A2/es unknown
- 2020-12-21 CL CL2020003319A patent/CL2020003319A1/es unknown
-
2024
- 2024-06-26 JP JP2024102884A patent/JP2024156656A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210022690A (ko) | 2021-03-03 |
| AU2019289202B2 (en) | 2024-10-31 |
| SG11202012726QA (en) | 2021-01-28 |
| ECSP20082338A (es) | 2021-02-26 |
| US20210205365A1 (en) | 2021-07-08 |
| CO2020016052A2 (es) | 2021-01-29 |
| EP3810646A1 (en) | 2021-04-28 |
| CR20200624A (es) | 2021-06-24 |
| MX2020014257A (es) | 2021-07-21 |
| JP2021527425A (ja) | 2021-10-14 |
| BR112020026233A2 (pt) | 2021-04-20 |
| PH12020500678A1 (en) | 2021-07-12 |
| JP2024156656A (ja) | 2024-11-06 |
| AU2019289202A1 (en) | 2021-01-14 |
| GB201810181D0 (en) | 2018-08-08 |
| CA3104079A1 (en) | 2019-12-26 |
| CN112601759A (zh) | 2021-04-02 |
| WO2019243835A1 (en) | 2019-12-26 |
| EA202190100A1 (ru) | 2021-04-23 |
| IL279469A (en) | 2021-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020016052A2 (es) | Receptores del factor de crecimiento quimérico | |
| MX2021000607A (es) | Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas. | |
| Knorr et al. | Clinical utility of natural killer cells in cancer therapy and transplantation | |
| Wrzesinski et al. | Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy | |
| CL2017002481A1 (es) | Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte progamada 1 (pd 1) para el tratamiento del cáncer | |
| AR057582A1 (es) | Agentes para suprimir la induccion de linfocitos t citotoxicos | |
| ES2910115T3 (es) | Células madre mesenquimales preacondicionadas con trombina para el tratamiento de la EIH neonatal | |
| Hendijani et al. | Human Wharton's jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| WO2015154012A8 (en) | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations | |
| Han et al. | Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response | |
| CL2017002357A1 (es) | Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos | |
| CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
| CO2020007275A2 (es) | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas | |
| MX2021014189A (es) | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| KR20170124467A (ko) | 저산소 조건을 이용한 면역세포의 증식 배양 방법 | |
| Bader et al. | Regulatory T cell approaches for graft-versus-host disease prevention | |
| Xue et al. | WT1-targeted immunotherapy of leukaemia | |
| KR20160144780A (ko) | 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법 | |
| WO2020037120A4 (en) | Il7-il15 txm compositions and methods | |
| Silvestre et al. | Engineered CD19-CAR NK cells as an off-the-shelf alternative to B cell leukemia and lymphoma treatment | |
| AR131998A1 (es) | Terapia celular para el tratamiento de enfermedades autoinmunes sistémicas | |
| CL2016001813A1 (es) | Uso de gsk-j4 en la prevención y/o tratamiento del rechazo de trasplantes. | |
| Dai et al. | Suppression of Allograft Rejection By a Novel Protein ESAT-6.: Abstract# D2759 |